NextGen geneC?RE Somatic endometrial
NextGen Genecore Somatic Endometrial Panel by NGS, FFPE Tissue** Price
Brief Details
What Is a NextGen geneCORE Somatic Endometrial Cancer Panel?
The NextGen geneCORE Somatic Endometrial Cancer Panel is an advanced diagnostic test that uses Next-Generation Sequencing (NGS) to generate a detailed genetic profile of endometrial cancer tumours. This comprehensive test examines specific genes known to be important in endometrial carcinoma development and progression.
The test helps detect specific genetic mutations within endometrial cancer tissue and assists doctors in classifying the tumour into distinct molecular subtypes for personalised treatment planning.
What Does the NextGen geneCORE Somatic Endometrial Cancer Panel Measure?
This comprehensive panel provides detailed genetic insights about your endometrial tumour:
- Somatic gene mutations: Identifies specific genetic changes in 38 key genes known to influence endometrial cancer development and progression.
- Molecular subtype classification: Categorises the cancer into four main groups: POLE ultramutated, mismatch repair deficient (MMRd), p53 abnormal, or no specific molecular profile (NSMP).
- Microsatellite instability (MSI): Assesses DNA repair system functionality, with high instability indicating potential responsiveness to immunotherapy.
- Gene fusions: Detects specific genetic rearrangements that may respond to targeted therapies.
- Mismatch repair pathway status: Evaluates the integrity of DNA repair mechanisms within cancer cells.
NextGen geneCORE Somatic Endometrial Cancer Panel: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen geneCORE Somatic Endometrial Cancer Panel?
This specialised test in oncology is not ordered based on symptoms alone but follows an endometrial cancer diagnosis. The initial symptoms that lead to cancer diagnosis and subsequently to this test include:
- Abnormal vaginal bleeding, particularly bleeding after menopause
- Bleeding between periods or unusually heavy menstrual periods
- Watery or foul-smelling vaginal discharge
- Persistent pelvic pain or discomfort in the lower abdomen
- Pain during sexual intercourse
Who Should Get a NextGen geneCORE Somatic Endometrial Cancer Panel?
This advanced genetic test is recommended for specific patient groups:
- Patients with a confirmed endometrial cancer diagnosis: Now recommended for virtually all newly diagnosed endometrial cancer patients.
- Individuals requiring treatment planning: Helps oncologists select the most appropriate therapy approach.
- Patients considering clinical trials: Genetic information may qualify patients for specific research studies.
- Those seeking personalised medicine approaches: Enables targeted therapy selection based on tumour genetics.
Why Is a NextGen geneCORE Somatic Endometrial Cancer Panel Done?
This test enables personalised medicine by providing crucial genetic information that helps oncologists select the most effective treatment strategy tailored to your tumour's unique genetic profile, potentially improving outcomes while avoiding ineffective treatments.
Importance of a NextGen geneCORE Somatic Endometrial Cancer Panel
This genetic test has revolutionised endometrial cancer management by moving from a one-size-fits-all approach to precise, molecularly guided treatment strategies. The test provides accurate prognostic information, with POLE-mutated cancers showing excellent outcomes, while p53-abnormal cancers tend to be more aggressive.
The results directly influence treatment choices, identifying patients who are excellent candidates for immunotherapy (MMR-deficient tumours) or targeted therapies based on specific tumour mutation burden. For low-risk molecular subtypes, doctors may recommend less aggressive treatments, sparing patients from unnecessary side effects while ensuring optimal care.
NextGen geneCORE Somatic Endometrial Cancer Panel Booking & Reports – Metropolis Healthcare India
How to Book a NextGen geneCORE Somatic Endometrial Cancer Panel?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen geneCORE Somatic Endometrial Cancer Panel', choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for the NextGen geneCORE Somatic Endometrial Cancer Panel Available Near You?
No, Metropolis Healthcare does not provide home sample collection for the NextGen geneCORE Somatic Endometrial Cancer Panel. This test requires tissue samples that are typically collected during medical procedures at healthcare facilities. The tissue is then sent to our pathology lab for analysis. Our trained team ensures safe handling and transportation of your tissue sample whilst maintaining strict quality protocols.
How Long Does It Take to Get a NextGen geneCORE Somatic Endometrial Cancer Panel Report?
Reports are usually available within 20 days once the sample reaches the lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen geneCORE Somatic Endometrial Cancer Panel Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen geneCORE Somatic Endometrial Cancer Panel Results
What Your NextGen geneCORE Somatic Endometrial Cancer Panel Results May Indicate
Your test results provide a comprehensive genetic profile that helps guide treatment decisions. Here's what different findings may indicate:
|
Parameters |
Result Type |
Clinical Significance |
|
POLE Gene Mutations |
Detected/Not Detected |
If detected, it indicates an excellent prognosis and potential for less aggressive treatment. |
|
TP53 Gene Mutations |
Detected/Not Detected |
If detected, it may indicate a more aggressive cancer requiring intensive treatment. |
|
MMR Pathway Genes |
Deficient/Proficient |
Deficient status suggests a good response to immunotherapy. |
|
BRCA1/BRCA2 Mutations |
Pathogenic/Benign |
Pathogenic variants may respond to PARP inhibitor therapies. |
|
Gene Fusions |
Detected/Not Detected |
If detected, it may qualify for specific targeted therapies. |
Conditions that May Affect NextGen geneCORE Somatic Endometrial Cancer Panel Accuracy
Several factors can influence the accuracy of your test results and should be considered when interpreting findings:
- Tissue quality and tumour content: Inadequate tumour cells in the sample may affect test sensitivity.
- Sample preservation methods: Improperly fixed or degraded tissue samples can impact DNA and RNA quality.
- Prior chemotherapy or radiation: Previous treatments may alter the genetic profile of remaining cancer cells.
- Sample contamination: Cross-contamination with normal tissue or other samples can affect results.
- Technical limitations: Certain genetic regions may be difficult to sequence due to their structure or composition.
- Tumour heterogeneity: Different areas of the same tumour may have varying genetic profiles.
How Is a NextGen geneCORE Somatic Endometrial Cancer Panel Done?
This specialised test involves several carefully coordinated steps to ensure accurate genetic analysis:
- Tissue sample collection: Your doctor collects tumour tissue during a biopsy, a surgical procedure, or from previously stored samples.
- Sample preparation: The tissue is processed and embedded in paraffin blocks for preservation and transport.
- Quality assessment: Laboratory technicians evaluate the sample to ensure adequate tumour content and tissue quality.
- DNA and RNA extraction: Genetic material is carefully extracted from the cancer cells within the tissue sample.
- Library preparation: The extracted genetic material is prepared using specialised techniques for sequencing.
- Next Generation Sequencing: Advanced NGS sequencing technology analyses multiple genes simultaneously for mutations and alterations.
- Data analysis: Sophisticated software processes the sequencing data to identify clinically relevant genetic changes.
- Report generation: Results are compiled into a comprehensive report with treatment recommendations.
How Should You Prepare for a NextGen geneCORE Somatic Endometrial Cancer Panel?
Preparation for this test primarily relates to the tissue collection procedure rather than the laboratory analysis itself:
- No fasting required: No dietary restrictions are necessary for the genetic analysis.
- No medication adjustments: Your current medications do not interfere with the genetic testing.
- Follow biopsy instructions: If tissue collection is pending, follow your doctor's pre-procedure guidance.
- Provide clinical history: Ensure your doctor has complete information about your symptoms and medical history.
Diseases that a NextGen geneCORE Somatic Endometrial Cancer Panel Can Help Detect
This comprehensive genetic panel provides valuable insights for several endometrial cancer-related conditions:
- Endometrial adenocarcinoma: The most common type of endometrial cancer, with various molecular subtypes.
- Serous carcinoma: An aggressive form of endometrial cancer often associated with p53 mutations
- Clear cell carcinoma: A rare but aggressive subtype of endometrial cancer
- Mixed endometrial carcinomas: Tumours containing multiple cancer cell types
- Hereditary cancer syndromes: May identify patients with Lynch syndrome or other inherited cancer predispositions.
- Recurrent endometrial cancer: Helps guide treatment decisions for cancer that returns after initial treatment.
NextGen geneCORE Somatic Endometrial Cancer Panel/Packages that You Can Book With Metropolis Healthcare
Related diagnostic tests are available at Metropolis Healthcare to provide a comprehensive evaluation alongside your genetic panel:
|
Test/Package Name |
Purpose/Highlights |
|
AFB-DNA (TB-PCR) Detection – Tissue/Biopsy/Lymph Nodes/Endometrium |
Detects tuberculosis DNA in tissue samples to rule out infectious causes |
|
Rapid culture method to identify mycobacterial infections in endometrial tissue |
|
|
Comprehensive histopathological examination with special staining and immunohistochemistry |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.